214 related articles for article (PubMed ID: 15607432)
1. Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process.
Bakris GL; Bank AJ; Kass DA; Neutel JM; Preston RA; Oparil S
Am J Hypertens; 2004 Dec; 17(12 Pt 2):23S-30S. PubMed ID: 15607432
[TBL] [Abstract][Full Text] [Related]
2. Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension.
Zieman SJ; Melenovsky V; Clattenburg L; Corretti MC; Capriotti A; Gerstenblith G; Kass DA
J Hypertens; 2007 Mar; 25(3):577-83. PubMed ID: 17278974
[TBL] [Abstract][Full Text] [Related]
3. A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys.
Vaitkevicius PV; Lane M; Spurgeon H; Ingram DK; Roth GS; Egan JJ; Vasan S; Wagle DR; Ulrich P; Brines M; Wuerth JP; Cerami A; Lakatta EG
Proc Natl Acad Sci U S A; 2001 Jan; 98(3):1171-5. PubMed ID: 11158613
[TBL] [Abstract][Full Text] [Related]
4. Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure.
Hartog JW; Willemsen S; van Veldhuisen DJ; Posma JL; van Wijk LM; Hummel YM; Hillege HL; Voors AA;
Eur J Heart Fail; 2011 Aug; 13(8):899-908. PubMed ID: 21669961
[TBL] [Abstract][Full Text] [Related]
5. Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease.
Cooper ME
Am J Hypertens; 2004 Dec; 17(12 Pt 2):31S-38S. PubMed ID: 15607433
[TBL] [Abstract][Full Text] [Related]
6. Cross-link breakers as a new therapeutic approach to cardiovascular disease.
Susic D
Biochem Soc Trans; 2007 Nov; 35(Pt 5):853-6. PubMed ID: 17956231
[TBL] [Abstract][Full Text] [Related]
7. Molecular basis of arterial stiffening: role of glycation - a mini-review.
Sell DR; Monnier VM
Gerontology; 2012; 58(3):227-37. PubMed ID: 22222677
[TBL] [Abstract][Full Text] [Related]
8. Advanced glycation end-product cross-link breakers. A novel therapeutic pathway for cardiovascular disease.
Hollenberg NK
Am J Hypertens; 2004 Dec; 17(12 Pt 2):21S-22S. PubMed ID: 15607431
[No Abstract] [Full Text] [Related]
9. Potential clinical utility of advanced glycation end product cross-link breakers in age- and diabetes-associated disorders.
Yamagishi S
Rejuvenation Res; 2012 Dec; 15(6):564-72. PubMed ID: 22950433
[TBL] [Abstract][Full Text] [Related]
10. The effect of an advanced glycation end-product crosslink breaker and exercise training on vascular function in older individuals: a randomized factorial design trial.
Oudegeest-Sander MH; Olde Rikkert MG; Smits P; Thijssen DH; van Dijk AP; Levine BD; Hopman MT
Exp Gerontol; 2013 Dec; 48(12):1509-17. PubMed ID: 24400341
[TBL] [Abstract][Full Text] [Related]
11. Crosslink breakers: a new approach to cardiovascular therapy.
Susic D; Varagic J; Ahn J; Frohlich ED
Curr Opin Cardiol; 2004 Jul; 19(4):336-40. PubMed ID: 15218393
[TBL] [Abstract][Full Text] [Related]
12. An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness.
Asif M; Egan J; Vasan S; Jyothirmayi GN; Masurekar MR; Lopez S; Williams C; Torres RL; Wagle D; Ulrich P; Cerami A; Brines M; Regan TJ
Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2809-13. PubMed ID: 10706607
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular and renal effects of a collagen cross-link breaker (ALT 711) in adult and aged spontaneously hypertensive rats.
Susic D; Varagic J; Ahn J; Frohlich ED
Am J Hypertens; 2004 Apr; 17(4):328-33. PubMed ID: 15062886
[TBL] [Abstract][Full Text] [Related]
14. Alagebrium chloride protects the heart against oxidative stress in aging rats.
Guo Y; Lu M; Qian J; Cheng YL
J Gerontol A Biol Sci Med Sci; 2009 Jun; 64(6):629-35. PubMed ID: 19299252
[TBL] [Abstract][Full Text] [Related]
15. The advanced glycation end product-lowering agent ALT-711 is a low-affinity inhibitor of thiamine diphosphokinase.
Krautwald M; Leech D; Horne S; Steele ML; Forbes J; Rahmadi A; Griffith R; Münch G
Rejuvenation Res; 2011 Aug; 14(4):383-91. PubMed ID: 21612515
[TBL] [Abstract][Full Text] [Related]
16. Advanced glycation end products accumulate in vascular smooth muscle and modify vascular but not ventricular properties in elderly hypertensive canines.
Shapiro BP; Owan TE; Mohammed SF; Meyer DM; Mills LD; Schalkwijk CG; Redfield MM
Circulation; 2008 Sep; 118(10):1002-10. PubMed ID: 18711013
[TBL] [Abstract][Full Text] [Related]
17. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes.
Candido R; Forbes JM; Thomas MC; Thallas V; Dean RG; Burns WC; Tikellis C; Ritchie RH; Twigg SM; Cooper ME; Burrell LM
Circ Res; 2003 Apr; 92(7):785-92. PubMed ID: 12623881
[TBL] [Abstract][Full Text] [Related]
18. Collagen cross-link breakers: a beginning of a new era in the treatment of cardiovascular changes associated with aging, diabetes, and hypertension.
Susic D; Varagic J; Ahn J; Frohlich ED
Curr Drug Targets Cardiovasc Haematol Disord; 2004 Mar; 4(1):97-101. PubMed ID: 15032654
[TBL] [Abstract][Full Text] [Related]
19. Alagebrium (ALT-711) improves the anti-hypertensive efficacy of nifedipine in diabetic-hypertensive rats.
Zhang B; He K; Chen W; Cheng X; Cui H; Zhong W; Li S; Wang L
Hypertens Res; 2014 Oct; 37(10):901-7. PubMed ID: 24965174
[TBL] [Abstract][Full Text] [Related]
20. Ageing of the conduit arteries.
Greenwald SE
J Pathol; 2007 Jan; 211(2):157-72. PubMed ID: 17200940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
